- PROFESSOR Neurology
Neurology, American Board of Psychiatry and Neurology
- Multiple Sclerosis
- Neuromyelitis optica
MD, Jefferson Medical College
Residency, Internal Medicine
Bronx Municipal Hospital Center
New York Hospital
- Fred D. Lublin, MD is the Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center. He is an internationally renowned authority on the clinical and scientific aspects of MS and one of the foremost experts in experimental therapies.
As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. In 2005, Dr. Lublin received a $25-million grant from the National Institutes of Health (NIH) to conduct a nationwide multi-center study on the effectiveness of combining two disease-modifying drugs. This grant was renewed in 2008, bringing the total allocated by the NIH to $44-million, one of the largest grants ever given for MS research.
Learn more about Dr. Lublin's work as Principal Investigator in the CombiRx clinical trial, as this study is known, in Inside Mount Sinai. He is also currently involved in several new clinical research protocols on promising agents for treating various aspects of MS.
Dr. Lublin was chairman of the National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new MS drugs; and he is currently chair of the Clinical Advisory Committee of the New York City Chapter of the National MS Society. Dr. Lublin and his colleagues at the National MS Society (USA) have redefined the clinical course definitions of MS.
Dr. Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. Dr. Lublin has served as a consultant to the NIH, as well as to pharmaceutical and biotech companies in all phases of drug development, and in preparation for drug presentation to the FDA and its advisory panels.
Dr. Lublin received his medical degree at Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.
In the News
Dr. Lublin discusses multiple sclerosis in The Daily News feature The Daily Check Up.
View the PDF.
DeAngelis T and Lublin F .D. Neurotherapeutics in Multiple Sclerosis: Novel Agents and Emerging Treatment Strategies. Mount Sinai Journal of Medicine 75:157-19-67, 2008.
Fazekas, F., Lublin, F.D., Li, D., Freedman, M.S., Hartung, H.P., Rieckmann, P., Soelberg Sørensen, P., Maas-Enriquez, M., Sommerauer, B., Hanna, K. For the PRIVIG Study Group, the UBC MS/MRI Research Group. Intravenous Immunoglobulin in Relapsing-Remitting Multiple Sclerosis- A Dose-Finding Trial. Neurology 71:265-271, 2008.
Goodman, A.D., Brown, T.R., Cohen, J.A., Krupp, L.B., Schapiro, R., Schwid, S.R., Cohen, R., Marinucci, L.N., Blight, A.R.; Fampridine MS-F202 Study Group. Dose Comparison Trial of Sustained-Release Fampridine in Multiple Sclerosis. Neurology 71:1134-1141, 2008.
Miller, D.H., Weinshenker, B.G., Filippi, M., Banwell, B.L., Cohen, J.A., Freedman, M.S., Galetta, S.L., Hutchinson, M., Johnson, R.T., Kappos, L., Kira, J., Lublin, F.D., McFarland, H.F., Montalban, X., Panitch, H., Richert, J.R., Reingold, S.C., Polman, C.H. Differential Diagnosis of Suspected Multiple Sclerosis: a consensus approach. Multiple Sclerosis 9:1157-1174, 2008.
Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C.H., O'Connor, P.W., Giovannoni, G., Phillips, J.T., Lublin, F.D., Pace, A., Kim, R., Hyde, R. Effect of Natalizumab on Clinical and Radiological Disease Activity in Multiple Sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurology 8:254-260, 2009.
Goodman, A.D., Rossman, H., Bar-Orm A., Miller, A., Miller ,D.H., Schmierer, K., Lublin ,F., Khan, O., Bormann, N.M., Yang, M., Panzara, M.A., Sandrock, A.,W., GLANCE Investigators. GLANCE: Results of a Phase 2, randomized, Double-Blind, Placebo -Controlled Study. Neurology 72:806-812, 2009.
Hutchinson, M., Kappos, L., Calabresi, P.A., Confavreux, C., Giovannoni, G., Galetta, S.L., Havrdova, E., Lublin, F.D., Miller, D.H., O'Connor, P.W., Phillips, J.T., Polman, C.H., Radue, E.W., Rudick, R.A., Stuart, W.H., Wajgt, A., Weinstock-Guttman, B., Wynn, D.R., Lynn, F., Panzara, M.A., AFFIRM and SENTINEL Investigators. The Efficacy of Natalizumab in Patients with Relapsing Multiple Sclerosis: Subgroup Analyses of AFFIRM and SENTINEL. Journal of Neurology 256:405-415, 2009.
Pandey, K., Lublin, F.D. Clinically Isolated Syndrome and Multiple Sclerosis: Rethinking the Arsenal. Current Treatment Options in Neurology 11:193-202, 2009
Mehta, L., Schwid, S., Arnold, D., Cutter, G., Aradhye, S., Balcer, L., Calabresi, P., Cohen, J., Cole, P., Glanzman, R., Goelz, S., Inglese, M., Kapoor, R., Kappos, L., Kreitman, R., Lublin, F., Mann, A., Marrie, R., O'Looney, P., Polman, C., Ravina, B., Reingold, S., Richert, J., Sandrock, A., Waubant, E. Proof of Concept Studies for Tissue-protective Agents in Multiple Sclerosis. Multiple Sclerosis 15:542-546, 2009.
Rudick, R.A., Pace, A., Rani, M.R., Hyde, R., Panzara, M., Appachi, S., Shrock, J., Maurer, S.L., Calabresi, P.A., Confavreux, C., Galetta, S.L., Lublin, F.D., Radue, E.W., Ransohoff, R.M. Effect of Statins on Clinical and Molecular Responses to Intramuscular Interferon beta-1a. Neurology 72:1989-1993, 2009
Straus Farber, R., Devilliers, L., Miller, A., Lublin, F., Law, M., Fatterpekar, G., Delman, B. and Naidich, T. Differentiating Multiple Sclerosis from Other Causes of Demyelination Using Diffusion Weighted Imaging of the Corpus Callosum. Journal of Magnetic Resonance Imaging. 30:732-736, 2009.
Rudick, R., Polman, C., Cohen, J., Walton, M., Miller, A., Confavreux, C., Lublin. F., Hutchinson, M., O'Connor, P., Schwid, S., Balcer, L., Lynn, F., Panzara, M., Sandrock, A. Assessing Disability Progression with the Multiple Sclerosis Functional Composite. Multiple Sclerosis15:984-997, 2009.
Berger, J.R., Centonze, D., Comi, G., Confavreux, C., Cutter, G., Giovannoni, G., Gold, R., Hartung, H.P., Lublin, F., Miravalle, A., Montalban, X., O'Connor, P., Olsson, T., Polman, C.H., Stuve, O., Wolinsky, J.S. and Ziemssen, T. Considerations on Discontinuing Natalizumab for the Treatment of Multiple Sclerosis. Annals of Neurology 68:409-411, 2010.
Lünemann, A., Tackenberg, B., DeAngelis, T., da Silva, R.B., Messmer, B., Vanoaica, L.D., Miller, A., Apatoff, B., Lublin, F.D., Lünemann, J.D. and Münz, C. Impaired IFN-γ Production and Proliferation of NK Cells in Multiple Sclerosis. International Immunology 23:139-148, 2011.
Polman, C.H., Reingold, S.C., Banwel,l B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., Montalban, X., O'Connor, P., Sandberg-Wollheim, M., Thompson, A.J., Waubant, E., Weinshenker, B. and Wolinsky, J.S. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology 69:292-302, 2011.
Phillips, J.T., Giovannoni, G., Lublin, F.D., O'Connor, P.W., Polman, C.H., Willoughby, E., Aschenbach, W., Pace, A., Hyde, R. and Munschauer, F.E. Sustained Improvement in Expanded Disability Status Scale as a New Efficacy Measure of Neurological Change in Multiple Sclerosis: Treatment Effects with Natalizumab in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis 17:970-979, 2011.
Lublin, F.D. and Deangelis, T.M. Multiple Sclerosis as a Model Neurologic Disease. Mount Sinai Journal of Medicine 78:159-160, 2011.
Repovic, P. and Lublin, F.D. Treatment of Multiple Sclerosis Exacerbations. Neurologic Clinics 29:389-400, 2011.
O'Connor, P.W., Goodman, A., Kappos, L., Lublin, F.D., Miller, D.H., Polman, C., Rudick, R.A., Aschenbach, W. and Lucas, N. Disease Activity Return During Natalizumab Treatment Interruption in Patients with Multiple Sclerosis. Neurology 76:1858-1865, 2011.
Lindsey, J.W., Scott, T.F., Lynch, S.G., Cofield, S.S., Nelson, F., Conwit, R., Gustafson, T., G.R. Cutter, G.R., Wolinsky, J.S., Lublin, F.D., for the CombiRx Investigators Group. The CombiRx Trial of Combined Therapy with Interferon and Glatiramer acetate in Relapsing Remitting MS: Design and Baseline Characteristics. Multiple Sclerosis and Related Diseases 1:81-86, 2012
Attending of the Year Award
Mount Sinai Medical Center Neurology Residents
2000 - Present
Chairman, Research Programs Advisory Committee
National Multiple Sclerosis Society
McEwan Visiting Professorship & Lecture in Neurology
University of Toronto
National Multiple Sclerosis Society, Delaware Valley Chapter
National Multiple Sclerosis Society, Delaware Valley Chapter
Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain : a journal of neurology 2014 Aug; 137(Pt 8).
Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of neurology 2013 Mar; 73(3).
Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Neurology 2014 Jun; 13(6).
O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of neurology 2013 Oct; 260(10).
Lublin FD. MS as a gateway disease. Journal of the neurological sciences 2013 Oct; 333(1-2).
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014 Jul; 83(3).
Narayana PA, Govindarajan KA, Goel P, Datta S, Lincoln JA, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS. Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study. NeuroImage. Clinical 2012; 2.
Nakao JH, Jafri FN, Shah K, Newman DH. Jolt accentuation of headache and other clinical signs: poor predictors of meningitis in adults. The American journal of emergency medicine 2014 Jan; 32(1).
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology 2011 Feb; 69(2).
Oynhausen S, Alcauskas M, Hannigan C, Bencosme Y, Müller M, Lublin F, Krieger S. Emergency medical care of multiple sclerosis patients: primary data from the mount sinai resource utilization in multiple sclerosis project. Journal of clinical neurology (Seoul, Korea) 2014 Jul; 10(3).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Lublin during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Acorda Therapeutics Inc.; Actelion Pharmaceuticals Ltd.; Bayer; Biogen Idec; EMD Serono, Inc. (Merck & Co., Inc.); F. Hoffman-La Roche Ltd.; Facilitate, LTD; Forward Pharma; MedImmune, LLC; Novartis; Osmotica Pharmaceutical Corp.; Questcor Pharmaceuticals, Inc.; Receptos Inc.; Revalesio Corporation; Teva Pharmaceutical Industries Ltd.; XenoPort, Inc.; sanofi-aventis; to-BBB
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Gerson Lehrman Group
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Faculty Practice Associates Floor 1st Floor Room MS Center
5 East 98th Street
New York, NY 10029
1468 Madison Avenue
New York, NY 10029